#### ARTICLE



# Inappropriate left ventricular mass after preeclampsia: another piece of the puzzle Inappropriate LVM and PE

Rossana Orabona<sup>1,2</sup> · Edoardo Sciatti<sup>3,4</sup> · Enrico Vizzardi<sup>3</sup> · Federico Prefumo<sup>1</sup> · Ivano Bonadei<sup>3</sup> · Adriana Valcamonico<sup>1</sup> · Marco Metra<sup>3</sup> · Roberto Lorusso<sup>4</sup> · Chahinda Ghossein-Doha<sup>2</sup> · Marc E A Spaanderman<sup>2</sup> · Tiziana Frusca<sup>1,5</sup>

Received: 28 June 2018 / Revised: 27 August 2018 / Accepted: 12 September 2018 / Published online: 14 December 2018 © The Japanese Society of Hypertension 2018

#### Abstract

Excessive left ventricular (LV) mass (LVM) increase results in inefficient LV work with high energy waste and a negative prognostic effect. We aimed to investigate the presence of inappropriate LVM and to calculate the myocardial mechanoenergetic efficiency index (MEEi) in asymptomatic women with a history of early-onset (EO) or late-onset (LO) pre-eclampsia (PE). Among all women diagnosed with PE in the years 2009-2013, after applying inclusion/exclusion criteria and cost-effectiveness analysis, we randomly selected thirty women who experienced EO-PE, thirty with a previous LO-PE and thirty healthy controls to undergo echocardiography from 6 months to 4 years after delivery. Data regarding gestational age (GA) and mean uterine artery (UtA) pulsatility index (PI) at PE onset were collected from medical records. All women were free from cardiovascular risk factors. LVM excess was calculated as the ratio between observed LVM and predicted LVM (by sex, stroke work and height), while MEEi was calculated as the ratio between stroke work and "double product" (to approximate energy consumption), indexed to LVM. Concentric remodeling was present in 60% of EO-PE and 53% of LO-PE. LVM excess was significantly more often present in the EO-PE group than in the control group. LVM was inappropriate in 52% of EO-PE and 17% of LO-PE. MEEi showed a tendency towards lower values in the EO-PE group. Multivariate regression analysis showed that both LVM excess and MEEi were independently associated with lower GA and higher mean UtA PI at PE onset. Inappropriate LVM with a tendency towards reduced MEEi in the first 4 years after delivery may partially explain the elevated cardiovascular risk in former pre-eclamptic women compared to the general population.

**Keywords** Pre-eclampsia  $\cdot$  left ventricular mass  $\cdot$  inappropriate  $\cdot$  echocardiography  $\cdot$  mechanoenergetic efficiency  $\cdot$  remodeling

These authors contributed equally: Rossana Orabona, Edoardo Sciatti

Rossana Orabona oraroxy@libero.it

- <sup>1</sup> Maternal Fetal Medicine Unit, Department of Obstetrics and Gynecology, University of Brescia, Brescia, Italy
- <sup>2</sup> Department of Obstetrics and Gynecology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center (MUMC), Maastricht, The Netherlands
- <sup>3</sup> Section of Cardiovascular Diseases, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy
- <sup>4</sup> Cardio-Thoracic Surgery Department, Heart & Vascular Centre, Maastricht University Medical Center (MUMC), Maastricht, The Netherlands
- <sup>5</sup> Department of Obstetrics and Gynecology, University of Parma, Brescia, Italy

# Introduction

Preeclampsia (PE) is one of the leading causes of maternal and perinatal morbidity and mortality worldwide [1]. The impact of PE does not end with delivery, as it is associated with a 2- to 7-fold increased risk for premature onset of cardiovascular (CV) disease [2]. Previous studies reported a high prevalence of persistent postpartum impairment in left ventricular (LV) geometry after PE [3–11], including concentric remodeling and hypertrophy, which may, at least in part, explain the elevated associated CV risk after PE. LV hypertrophy represents the structural adaptation to cardiac overload thanks to a higher compensatory LV mass (LVM). However, in some cases, LVM exceeds the need to sustain cardiac workload, resulting in "inappropriate LVM", which is linked to functional cardiac impairment, resulting in energy waste and reduced LV mechanoenergetic efficiency (MEE) [12–14]. Moreover, it is associated with a suboptimal CV risk profile [15–18] and cardiac adverse events [19, 20].

The aim of the present study was to assess the presence of inappropriate LVM and the extent of MEE in women with a history of early-onset (EO) and late-onset (LO) PE. We also aimed to investigate the relationship between LVM excess and MEE and obstetric parameters, including gestational age (GA) at PE onset, intrauterine growth restriction (IUGR) and uterine artery (UtA) Doppler velocimetry.

# Methods

## **Subjects**

This was a cross-sectional single-center case-control study, in compliance with the 1975 Declaration of Helsinki, approved by the local Medical Ethics committee and conducted according to Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [21]. We retrospectively searched our electronic database for all women diagnosed with PE at the Maternal Fetal Medicine Unit of the Department of Obstetrics and Gynecology, University of Brescia, Italy between January 2009 and December 2013. PE was defined, according to the International Society for the Study of Hypertension in Pregnancy, as a blood pressure of at least 140/90 mmHg, on two occasions 4-6 h apart, after the 20<sup>th</sup> week of gestation, in previously normotensive women, accompanied by proteinuria  $\geq$  300 mg/24 h [22]. EO-PE was defined as PE requiring delivery before 34 weeks of gestation.

All women were approached by phone between 6 months and 4 years after delivery to assess their eligibility. We excluded women with any of the following CV risk factors: smoking habit, dyslipidemia, overweight/obesity, diabetes mellitus, or chronic hypertension, as well as those who had multiple pregnancy, fetal aneuploidy or malformation, maternal cardiopathy, nephropathy or immune disorder, or PE superimposed on chronic hypertension. In addition, we only included women with normal blood pressure values and the absence of pathological proteinuria 6 months after delivery. Considering the sample-size calculation, costeffectiveness and available resources, only 60 subjects (30 EO-PE and 30 LO-PE) were randomly selected and requested to attend for postpartum follow-up. Thirty healthy women matched for age, body mass index and parity and without CV risk factors who delivered in our hospital during the same days as the enrolled cases were selected as controls.

Demographic and clinical data during pregnancy were collected from obstetric charts of all included subjects.

Small-for-gestational age infants were defined as a birth weight below the  $10^{th}$  percentile for GA on the basis of national growth charts [23]. IUGR was defined as fetal abdominal circumference <  $10^{th}$  percentile, according to local standards [23], with umbilical artery pulsatility index (PI) > 95<sup>th</sup> percentile at sonography. All prenatal ultrasound scans had been performed by experienced sonographers using an iU22 ultrasound system equipped with a V6-2 curved-array volume transducer (Philips Healthcare, Bothell, WA, USA). UtA Doppler measurements were obtained at the apparent crossover of the uterine and external iliac arteries. The PIs of both UtAs were measured, and their mean was calculated.

After providing written informed consent to participate, all women underwent peripheral blood pressure measurement and echocardiography at our Cardiology Unit, in a single, temperature-controlled room. To limit intra- and interobserver variability, the study was carried out by a single expert echocardiographer (E.V.) who was blinded to the patients' prior medical history.

#### **Blood pressure measurement**

Blood pressure was assessed using a standard, calibrated, electronic sphygmomanometer (OMRON Healthcare, Hoofddorp, The Netherlands), with the woman in a resting state and sitting at a  $45^{\circ}$  angle. Systolic blood pressure (SBP) was considered to be high if it was  $\geq 140$  mmHg, while high diastolic blood pressure (DBP) was defined as a value  $\geq 90$  mmHg. BP was measured initially in each arm, and the arm with the highest sitting DBP reading was used for a further two measurements, with the mean of the three measurements recorded. Every effort was made to have the same staff member obtain blood pressure measurements in every patient, at the same time of day, using the same equipment. Mean arterial pressure (MAP) was calculated as: (SBP + 2 × DBP)/3.

## Echocardiography

Echocardiographic examinations were performed using a Vivid 7 ultrasound machine (GE Healthcare, Milwaukee, WI, USA), equipped with a 3.5-MHz transducer. Digital loops were stored on the hard disk of the ultrasound machine and transferred to an EchoPac workstation (GE Healthcare) for offline analysis. Participants were placed in the left lateral decubitus position, and images were acquired from standard parasternal and apical views. LV dimensions, volumes and LVM were obtained according to current guidelines [24], and the LV ejection fraction (LVEF) was calculated using Simpson's biplane method [24]. LV diastolic function was defined according to published guidelines, assessing transmitral Doppler inflows and tissue

Doppler imaging at basal segments [25]. Valvular alterations were screened according to published guidelines [26, 27].

### Inappropriate LVM and myocardial MEEi

LVM (in g) was obtained by the equation  $0.8 \times (1.04 \times ((LVEDD + IVST + PWT)^3 - LVEDD^3)) + 0.6$ , and relative wall thickness (RWT) was calculated as  $2 \times PWT/$ LVEDD, where LVEDD is LV end-diastolic diameter, IVST is the interventricular septal thickness and PWT is the posterior wall thickness, at end-diastole [24]. Concentric remodeling was defined by RWT > 0.42 with a normal LVM, and concentric hypertrophy by RWT > 0.42 and LVM index > 95 g/m<sup>2</sup> (for females) [24].

Predicted LVM (pLVM) was calculated from stroke work (SW), sex and body size (as height (h) in meters to the 2.7 power) by the following validated equation: [28, 29]  $g = 55.37 + (6.64 \times h^{2.7}) + (0.64 \times SW)$ (in pLVM (18.07 × sex). SW can be computed as:  $SW = SBP \times SV \times$ 0.0144, where SV is echocardiographic stroke volume, calculated using the z-derived method to estimate LV volumes [30]. The term 0.0144 converts mmHg  $\times$  cm<sup>3</sup> to  $g \times m$ . Sex was assigned the values of 1 for men and 2 for women. An excess of LVM was calculated as the ratio between the observed LVM and pLVM. The excess of LVM over 128% of the value predicted from individual hemodynamic load was defined as "inappropriate LVM", whereas a LVM/pLVM ratio < 73% as "inadequate LVM" [28].

The mechanical efficiency of a system is the ratio between developed work and the corresponding energy consumption. To estimate myocardial MEE, two factors are required: work and energy consumption, as previously demonstrated [14, 31]. Total external myocardial work can be estimated as SW, as indicated above (Fig. 1). Energy consumption would ideally be determined by coronary sinus catheterization to measure real-time myocardial oxygen consumption (MVO<sub>2</sub>). More simply, MVO<sub>2</sub> can be calculated as the so-called "double product" (DP), that is,  $SBP \times HR$ . Thus, myocardial MEE—as the ratio between developed external work and an estimate of MVO<sub>2</sub> - can be expressed as: MEE = SW/DP = SV/HR. HR can also be expressed in seconds, as the time of the cardiac cycle by dividing HR by 60. Thus, myocardial mechanical efficiency can be measured as the ideal amount of blood pumped by one single heart beat in 1 s. Due to the strong relationship between MEE and LVM, MEE can be divided by LVM to obtain an estimate of myocardial MEE per gram of LVM [i.e., MEE index (MEEi), expressed in mL/s per g].





Fig. 1 Left ventricular pressure–volume curve. Myocardial energy is the sum of external work (namely, stroke work, in orange) and elastic potential energy (in yellow). DBP diastolic blood pressure, EDP enddiastolic pressure, EDPVR end-diastolic pressure–volume relationship, EDV end-diastolic volume, ESP end-systolic pressure, ESPVR endsystolic pressure–volume relationship, PE potential energy, ESV endsystolic volume, SBP systolic blood pressure, SV stroke volume, SW stroke work

## **Statistical analysis**

Continuous variables were visually tested for normality using Q–Q plots and are expressed as the means and standard deviations (SDs); categorical variables are expressed as frequencies (n) and percentages of the sample.

After Levene's test for homoscedasticity, Welch's unequal variances analysis of variance (ANOVA) was performed to analyze the difference between means for continuous variables (independent samples Welch's *t* test if two groups), and Dunnett C test for *post hoc* analysis. The  $\chi^2$  test was used for assessing differences between proportions.

Multivariate regression analysis using the "enter" method was performed to assess the association between LVM/ pLVM and MEEi from 6 months to 4 years after delivery (as the dependent variables) and pregnancy data from both PE groups as the independent variables (GA, SBP, DBP, UtA-PI at diagnosis of PE, birth weight percentile). No a priori sample size calculation was possible due to the lack of data for the parameters investigated in this clinical setting. *Post hoc* sample size calculation showed that the statistics were adequate with an 85% power and a 0.05 Type I error risk for all parameters. Statistical analysis was performed using IBM SPSS Statistics 20 for Windows (SPSS, Inc., Chicago, IL). All values were two-tailed; statistical significance was set at p < 0.05. preeclampsia, PE preeclampsia



# Results

In our electronic database, we identified 388 women with a previous pregnancy complicated by PE between January 2009 and December 2013. Among these women, 41 who experienced EO-PE and 57 who had had LO-PE were eligible for the study. According to cost-effectiveness 30 cases from each group were randomly included (Fig. 2). All women were free from any medication at the time of cardiologic assessment, including oral contraceptives. Pregnancy data and baseline patient characteristics are reported in Table 1. Blood pressure measurements, although within the normal range (<140/90 mmHg), were significantly higher in the EO-PE group than in the LO-PE group; DBP was also higher than in the controls.

Table 2 shows that all patients had normal LVM and pLVM, with statistically nonsignificant tendencies towards higher LVM in both PE groups than in the controls. No woman had LV hypertrophy. However, concentric remodeling was higher in both PE groups than in the controls (60% vs 53% vs 0%, respectively; p < 0.001). Consequently, LVM/pLVM was significantly increased in these

groups, with a significant difference between EO-PE and the controls. LVM was more often inappropriate in the EO-PE group compared to the other two groups (53 vs. 17 vs. 0%, respectively; p < 0.001). MEE and MEEi did not show any significant differences among the three groups, with a tendency towards lower values in the EO-PE group. No woman had inadequate LVM. Grade I diastolic dysfunction was present in only 10% of the EO-PE group (p = 0.045)

The results of the multivariable analysis are reported in Table 3. GA at the diagnosis of PE, as well as blood pressure at PE onset, UtA-PI and birth-weight percentile were all independently associated with LVM excess (LVM/ pLVM) and MEEi.

## Discussion

The main findings of the present study are that: (1) even in the absence of LV hypertrophy, approximately half of women with a previous EO-PE and one-sixth of those with a previous LO-PE showed inappropriate LVM; (2) women with a previous EO-PE had a tendency towards lower MEEi Table 1 Demographic andclinical characteristics of studypopulation of women withprevious singleton pregnancycomplicated by early-onset (EO)or late-onset (LO) pre-eclampsia(PE) and controls, obtainedretrospectively

<u></u>				
Variable	EO-PE group $(n = 30)$	LO-PE group $(n = 30)$	Controls $(n = 30)$	P value
Maternal age at delivery (years)	$36 \pm 4$	$34 \pm 6$	$35 \pm 4$	0.061
Maternal age at assessment (years)	$38 \pm 4$	$36 \pm 6$	$37 \pm 4$	0.084
Time from delivery (years)	$2.3 \pm 0.7$	$2.5 \pm 0.8$	$2.2 \pm 0.6$	0.115
BMI (kg/m <sup>2</sup> )	$23.2 \pm 2.3$	$22.3 \pm 2.4$	$23.1 \pm 2.5$	0.329
BSA (m <sup>2</sup> )	$1.68 \pm 0.14$	$1.67 \pm 0.12$	$1.62\pm0.08$	0.112
SBP (mmHg)	$125 \pm 13^{\ddagger}$	$116 \pm 11$	$119 \pm 8$	0.007
DBP (mmHg)	$80 \pm 9^{*\ddagger}$	$73 \pm 9$	$74 \pm 6$	0.003
MAP (mmHg)	$95 \pm 10^{*^{\ddagger}}$	87 ± 9	$89 \pm 4$	0.001
HR (bpm)	$78 \pm 9$	$77 \pm 10$	$79 \pm 7$	0.604
Parity				0.136
Nulliparous	18 (60.0%)	24 (80.0%)	21 (70.0%)	
Primiparous	9 (30.0%)	3 (10.0%)	6 (20.0%)	
Multiparous	3 (10.0%)	3 (10.0%)	3 (10.0%)	
GA at diagnosis of PE (weeks)	$27^{+5} \pm 2^{+4}$	$36^{+4} \pm 1^{+2}$	-	< 0.001
Mean UtA-PI at diagnosis of PE	$1.56 \pm 0.39$	$1.13 \pm 0.43$	-	0.001
SBP at diagnosis of PE (mmHg)	$161 \pm 27$	$163 \pm 13$	-	0.007
DBP at diagnosis of PE (mmHg)	$117 \pm 33$	$104 \pm 18$	-	0.003
Proteinuria (mg/24 h)	$3258 \pm 926$	$3012 \pm 2618$	-	0.841
GA at delivery (weeks)	$30^{+6+} \pm 3^{+6*}$	$37^{+1} \pm 1^{+2\dagger}$	$39^{+1} \pm 1^{+0}$	0.033
Cesarean section	30 (100.0%)* <sup>‡</sup>	17 (56.7%) <sup>†</sup>	5 (16.7%)	< 0.001
IUGR	23 (76.7%)	13 (43.3%)	-	< 0.001
Male sex	15 (50.0%)	10 (33.3%)	17 (56.7%)	0.405
Birth weight (g)	$928 \pm 539^{\ddagger}$	$2483 \pm 561^{\dagger}$	$3315 \pm 485$	< 0.001
Birth-weight percentile	$14.1 \pm 20.7*$	$20.7 \pm 22.3^{\dagger}$	$48.0 \pm 21.9$	0.022
Maternal complications				_
HELLP syndrome		_	_	
Eclampsia	_	_	_	
Placental abruption	1 (3.3%)	_	_	
Disseminated intravascular coagulation	1 (3.3%)			

The data are given as mean  $\pm$  SD, *n* (%)

*BMI* body mass index, *BSA* body surface area, *DBP* diastolic blood pressure, *DIC* disseminated intravascular coagulation, *GA* gestational age, *HR* heart rate, *IUGR* intrauterine growth restriction, *MAP* mean arterial pressure, *PI* pulsatility index, *SBP* systolic blood pressure, *UtA* uterine artery

Post-hoc two-sample comparison of groups: \*P < 0.05, EO-PE vs. controls,  $\dagger P < 0.05$ , LO-PE vs. controls,  $\ddagger P < 0.05$ , EO-PE vs. LO-PE

than LO-PE and controls; and (3) GA and UtA-PI at PE onset and birth-weight percentile were independently associated with LVM excess and MEEi.

Women with a previous pregnancy complicated by PE, particularly EO-PE, are characterized by a relatively high proportion of asymptomatic LV systolic and/or diastolic dysfunction [3–11, 32, 33]. More in detail, Melchiorre *et al.* demonstrated 40 and 20% prevalence rates of unfavorable LV remodeling and/or hypertrophy one year postpartum in EO-PE and LO-PE, respectively [3]. These abnormalities were associated with the development of clinical hypertension in 50% of cases within 1 to 2 years after pregnancy

[3]. Similarly, Ghossein-Doha *et al.* found that the development of hypertension in initially normotensive formerly pre-eclamptic women was preceded by the increase of LVM and that PE was an independent predictor for developing structural cardiac remodeling 4–7 years later [34]. We recently extended these data, describing a frequent subclinical impairment in LV contractility and relaxation at short-medium term after delivery [33]. In contrast to the subjects studied by Melchiorre *et al.*, our cohort was normotensive and characterized by the absence of LV hypertrophy. Nevertheless, we hereby demonstrated that many apparently healthy women show an excess of LVM that

Table 2 Demographic andclinical characteristics of studypopulation of women withprevious singleton pregnancycomplicated by early-onset (EO)or late-onset (LO) pre-eclampsia(PE) and controls, obtainedretrospectively

Table 3Multivariate regressionanalysis, run on the 60 caseswith previous pre-eclampticpregnancy, to assess linearassociation between LVMexcess and MEEi (as dependentvariables) and obstetric data (asindependent variables).95%confidence intervals are also

shown

Variable	EO-PE group $(n = 30)$	LO-PE group $(n = 30)$	Controls $(n = 30)$	Р
LVEF (%)	$56 \pm 7^{*^{\ddagger}}$	61 ± 5	$63 \pm 4$	< 0.001
Stroke volume (mL) <sup>a</sup>	$46 \pm 11$	$50 \pm 15$	$48 \pm 18$	0.669
LVM (g)	$109.9 \pm 29.4$	$108.1 \pm 17.1$	$97.9 \pm 17.5$	0.081
LVMi (g/m <sup>2</sup> )	$64.7 \pm 13.6$	$64.7 \pm 8.2$	$61.2 \pm 10.8$	0.389
RWT	$0.42\pm0.09*$	$0.44 \pm 0.11^{\dagger}$	$0.36 \pm 0.06$	0.238
Concentric remodelling	18 (60.0%)*	16 (53.3%) <sup>†</sup>	0 (0.0%)	< 0.001
E/A ratio	$1.24\pm0.19$	$1.27 \pm 0.25$	$1.18 \pm 0.09$	0.212
E wave deceleration time (ms)	$208 \pm 70$	$185 \pm 42$	$185 \pm 13$	0.136
E/E'	$7.20 \pm 1.34$	$7.37 \pm 0.63$	$6.78 \pm 1.13$	0.091
Grade I diastolic dysfunction	3 (10.0%)* <sup>‡</sup>	0 (0.0%)	0 (0.0%)	0.045
pLVM (g) <sup>a</sup>	$96.7 \pm 12.6$	$97.7 \pm 16.2$	$95.1 \pm 19.2$	0.820
LVM/pLVM (%) <sup>a</sup>	$123 \pm 36*$	$112 \pm 15$	$104 \pm 16$	0.020
Inappropriate LVM <sup>a</sup>	12 (52.2%)* <sup>‡</sup>	5 (16.7%) <sup>†</sup>	0 (0.0%)	0.002
MEE (mL/s) <sup>a</sup>	$35.2 \pm 10.2$	$39.4 \pm 13.6$	$36.7 \pm 14.4$	0.502
MEEi (mL/s/g) <sup>a</sup>	$0.41 \pm 0.27$	$0.47 \pm 0.14$	$0.48 \pm 0.12$	0.498

Data are given as mean  $\pm$  SD, n (%)

*LV* left ventricular, *LVEF* left ventricular ejection fraction, *LVM* left ventricular mass, *LVMi* left ventricular mass index, *MEE* mechano-energetic efficiency, *MEEi* mechano-energetic efficiency index, *pLVM* predicted left ventricular mass, *RWT* relative wall thickness

Post-hoc two-sample comparison of groups: \*P < 0.05, EO-PE vs. controls,  $\dagger P < 0.05$ , LO-PE vs. controls,  $\ddagger P < 0.05$ , EO-PE vs. LO-PE

<sup>a</sup>Data available only in 23/30 (76.7%) EO-PE

	LVM excess (LVM/pLVM)		MEEi	
	β	P value	β	P value
GA	-1.013 (-2.156 to -0.009)	0.049	0.013 (0.007 to 0.019)	< 0.001
SBP	2.090 (1.557 to 2.624)	< 0.001	-0.006 (-0.009 to -0.003)	< 0.001
DBP	2.825 (2.359 to 3.290)	< 0.001	-0.012 ( $-0.014$ to $-0.009$ )	< 0.001
BW percentile	-0.519 (-0.849 to -0.189)	0.004	0.002 (0.000 to 0.004)	0.028
UtA-PI	57.649 (46.846 to 68.453)	< 0.001	-0.277 (-0.338 to -0.216)	< 0.001

*BW* birth weight, *DBP* diastolic blood pressure at diagnosis, *GA* gestational age at diagnosis, *LVM* left ventricular mass, *MEEi* mechano-energetic efficiency index, *pLVM* predicted left ventricular mass, *SBP* systolic blood pressure at diagnosis, *UtA-PI* mean uterine artery pulsatility index at diagnosis

cannot be expected by hemodynamic load based on blood pressure or body composition. We attempt to explain this issue considering two aspects. First, these women showed high prevalence rates of endothelial dysfunction and arterial stiffness [35–37], with impaired aortic elastic properties [36] and increased aortic elastance (i.e., stiffness) [33]. This phenotype is responsible for increased afterload and reduced ventricular-arterial coupling during the ejection phase, thus favoring an inappropriately high LVM. Second, the presence of LV fibrosis documented in these women may increase LVM without a corresponding increase in LV work [38]. As a consequence, the left ventricle is more stiffened (high LV elastance), which leads to impaired diastolic function [33]. This effect could be the consequence of a relative myocardial ischemia due to the mismatch between increased afterload and reduced coronary perfusion in diastole, both related to arterial stiffness. A fibrotic, stiffened and remodeled left ventricle works at low efficiency and wastes energy. If the aorta is rigid, as it is in this case, the efficiency is even lower, as we demonstrated [33, 36]. Furthermore, we found a statistically nonsignificant tendency towards reduced MEEi in the EO-PE group, suggesting a low contraction efficiency at the myocyte level.

Inappropriate LVM has been extensively studied in hypertensive subjects, as it is associated with LV geometric and functional abnormalities [12, 13], thus favoring wasted LV energy and reduced MEE [14]. Moreover, inappropriate

LVM is associated with a high-risk CV profile [15–18] and predicts adverse events [19, 20]. From epidemiological studies, pregnancies complicated by PE are associated with a higher risk of CV events later in life with a two-fold CV mortality (eight-fold if EO-PE) [2, 39]. For this reason, a history of PE has been added to traditional CV risk factors [40]. It may be that inappropriate LVM may play a role in increasing the CV risk of these women.

Our study suffers from some limitations. First, a small number of patients was involved. Second, the lack of a preconceptional and gestational echocardiographic evaluation to compare our findings prevented us from definitely knowing if the LVM excess with reduced MEE is a consequence of PE or indicates an alteration already present before pregnancy. Moreover, SV measured by M-mode echocardiography may be imprecise. However, in an epidemiological study, M-mode SV was very closely related to Doppler SV (mean difference  $1.6 \pm 5.0$  mL/beat), which was validated against invasive SV [41]. Finally, in order to relate external work with MVO<sub>2</sub> and to estimate MEE, we used simple formulas based on simple assumptions, which have already been used in many different circumstances [12-20, 28-31] and validated against invasive methods [42-45].

In conclusion, to the best of our knowledge, this is the first study to assess LVM excess and MEE in asymptomatic women with a history of PE. Our findings suggest that EO-PE is characterized by LVM excess at short-medium term after delivery, with a tendency towards reduced MEE. These findings can provide another possible explanation for the higher risk of CV events later in life in these women with respect to the general female population of the same age.

#### **Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

# References

- Cunningham FG, Lindheimer MD. Hypertension in pregnancy. N Engl J Med. 1992;326:927–32.
- Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335:974.
- Melchiorre K, Sutherland GR, Liberati M, Thilaganathan B. Preeclampsia is associated with persistent postpartum cardiovascular impairment. Hypertension. 2011;58:709–15.
- Ghi T, Degli Esposti D, Montaguti E, Rosticci M, De Musso F, Youssef A, et al. Post-partum evaluation of maternal cardiac function after severe preeclampsia. J Matern Fetal Neonatal Med. 2014;27:696–701.
- 5. Evans CS, Gooch L, Flotta D, Lykins D, Powers RW, Landsittel D, et al. Cardiovascular system during the postpartum state in

women with a history of preeclampsia. Hypertension. 2011;58:57-62.

- Strobl I, Windbichler G, Strasak A, Weiskopf-Schwendinger V, Schweigmann U, Ramoni A, et al. Left ventricular function many years after recovery from pre-eclampsia. BJOG. 2011;118:76–83.
- Tyldum EV, Backe B, Støylen A, Slørdahl SA. Maternal left ventricular and endothelial functions in preeclampsia. Acta Obstet Gynecol Scand. 2012;91:566–73.
- Simmons LA, Gillin AG, Jeremy RW. Structural and functional changes in left ventricle during normotensive and preeclamptic pregnancy. Am J Physiol Heart Circ Physiol. 2002;283: H1627–1633.
- Valensise H, Vasapollo B, Gagliardi G, Novelli GP. Early and late preeclampsia: two different maternal hemodynamic states in the latent phase of the disease. Hypertension. 2008;52:873–80.
- Breetveld NM, Ghossein-Doha C, van Kuijk SM, van Dijk AP, van der Vlugt MJ, Heidema WM, et al. Prevalence of asymptomatic heart failure in formerly pre-eclamptic women: a cohort study. Ultrasound Obstet Gynecol. 2017;49:134–42.
- Ghossein-Doha C, van Neer J, Wissink B, Breetveld NM, de Windt LJ, van Dijk AP, et al. Pre-eclampsia: an important risk factor for asymptomatic heart failure. Ultrasound Obstet Gynecol. 2017;49:143–9.
- de Simone G, Kitzman DW, Palmieri V, Liu JE, Oberman A, Hopkins PN, et al. Association of inappropriate left ventricular mass with systolic and diastolic dysfunction The HyperGEN study. Am J Hypertens. 2004;17:828–33.
- Chinali M, De Marco M, D'addeo G, Benincasa M, Romano C, Galderisi M, et al. Excessive increase in left ventricular mass identifies hypertensive subjects with clustered geometric and functional abnormalities. J Hypertens. 2007;25:1073–8.
- de Simone G, Chinali M, Galderisi M, Benincasa M, Girfoglio D, Botta I, et al. Myocardial mechanoenergetic efficiency in hypertensive adults. J Hypertens. 2009;27:650–5.
- Palmieri V, de Simone G, Roman MJ, Schwartz JE, Pickering TG, Devereux RB. Ambulatory blood pressure and metabolic abnormalities in hypertensive subjects with inappropriately high LV mass. Hypertension. 1999;34:1032–40.
- Celentano A, Palmieri V, Esposito ND, Pietropaolo I, Crivaro M, Mureddu GF, et al. Inappropriate left ventricular mass in normotensive and hypertensive patients. Am J Cardiol. 2001;87:361–3.
- Palmieri V, Wachtell K, Gerdts E, Bella JN, Papademetriou V, Tuxen C, et al. Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study. Am Heart J. 2001;141:784–91.
- Mureddu GF, Pasanisi F, Palmieri V, Celentano A, Contaldo F, de Simone G. Appropriate or inappropriate left ventricular mass in the presence or absence of prognostically adverse left ventricular hypertrophy. J Hypertens. 2001;19:1113–9.
- de Simone G, Palmieri V, Koren MJ, Mensah GA, Roman MJ, Devereux RB. Prognostic implications of the compensatory nature of left ventricular mass in arterial hypertension. J Hypertens. 2001;19:119–25.
- de Simone G, Verdecchia P, Pede S, Gorini M, Maggioni AP. Prognosis of inappropriate left ventricular mass in hypertension: the MAVI Study. Hypertension. 2002;40:470–6.
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–9.
- 22. Brown MA, Lindheimer MD, de Swiet M, van Assche A, Moutquin JM. The classification and diagnosis of hypertensive disorders of pregnancy: statement from the International Society

for the Study of Hypertension in Pregnancy. Hypertens Pregnancy. 2001;20:IX-XIV.

- Todros T, Ferrazzi E, Groli C, Nicolini U, Parodi L, Pavoni M, et al. Fitting growth curves to head and abdomen measurements of the fetus; a multicentric study. J Clin Ultrasound. 1987;15:95–105.
- 24. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1–39.
- Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of LV diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22:107–33.
- 26. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, et al. American Society of Echocardiography. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003;16:777–802.
- Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, et al. EAE/ASE. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J Echocardiogr. 2009;10:1–25.
- de Simone G, Devereux RB, Kimball TR, Mureddu GF, Roman MJ, Contaldo F, et al. Interaction between body size and cardiac workload: influence on left ventricular mass during body growth and adulthood. Hypertension. 1998;31:1077–82.
- Cioffi G, Faggiano P, Vizzardi E, Tarantini L, Cramariuc D, Gerdts E, et al. Prognostic effect of inappropriately high left ventricular mass in asymptomatic severe aortic stenosis. Heart. 2011;97:301–7.
- 30. de Simone G, Devereux RB, Ganau A, Hahn RT, Saba PS, Mureddu GF, et al. Estimation of left ventricular chamber and stroke volume by limited M-mode echocardiography and validation by two-dimensional and Doppler echocardiography. Am J Cardiol. 1996;78:801–7.
- de Simone G, Izzo R, Losi MA, Stabile E, Rozza F, Canciello G, et al. Depressed myocardial energetic efficiency is associated with increased cardiovascular risk in hypertensive left ventricular hypertrophy. J Hypertens. 2016;34:1846–53.
- Orabona R, Vizzardi E, Sciatti E, Prefumo F, Bonadei I, Valcamonico A, et al. Maternal cardiac function after HELLP syndrome: an echocardiography study. Ultrasound Obstet Gynecol. 2017;50:507–13.
- Orabona R, Vizzardi E, Sciatti E, Bonadei I, Valcamonico A, Metra M, et al. Insights into cardiac alterations after pre-eclampsia: an echocardiographic study. Ultrasound Obstet Gynecol. 2017;49:124–33.

- Ghossein-Doha C, Peeters L, van Heijster S, van Kuijk S, Spaan J, Delhaas T, et al. Hypertension after preeclampsia is preceded by changes in cardiac structure and function. Hypertension. 2013;62:382–90.
- Hausvater A, Giannone T, Sandoval YH, Doonan RJ, Antonopoulos CN, Matsoukis IL, et al. The association between preeclampsia and arterial stiffness. J Hypertens. 2012;30:17–33.
- 36. Orabona R, Sciatti E, Vizzardi E, Bonadei I, Valcamonico A, Metra M, et al. Elastic properties of ascending aorta in women with previous pregnancy complicated by early- or late-onset preeclampsia. Ultrasound Obstet Gynecol. 2016;47:316–23.
- 37. Orabona R, Sciatti E, Vizzardi E, Bonadei I, Valcamonico A, Metra M, et al. Endothelial dysfunction and vascular stiffness in women with previous pregnancy complicated by early or late preeclampsia. Ultrasound Obstet Gynecol. 2017;49:116–23.
- Orabona R, Sciatti E, Vizzardi E, Bonadei I, Prefumo F, Valcamonico A, et al. Ultrasound evaluation of left ventricular and aortic fibrosis after pre-eclampsia. Ultrasound Obstet Gynecol. 2018;52:648–53.
- Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ. 2001;323:1213–7.
- Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. Circulation. 2011;123:1243–62.
- 41. Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Wood EA, Howard BV, et al. for the Strong Heart Study Investigators. Relations of Doppler stroke volume and its components to left ventricular stroke volume in normotensive and hypertensive American Indians: the Strong Heart Study. Am J Hypertens. 1997;10:619–28.
- 42. Gobel FL, Norstrom LA, Nelson RR, Jorgensen CR, Wang Y. The rate-pressure product as an index of myocardial oxygen consumption during exercise in patients with angina pectoris. Circulation. 1978;57:549–56.
- 43. Vanoverschelde JL, Wijns W, Essamri B, Bol A, Robert A, Labar D, et al. Hemodynamic and mechanical determinants of myocardial O2 consumption in normal human heart: effects of dobutamine. Am J Physiol. 1993;265:H1884–92.
- 44. Laine H, Katoh C, Luotolahti M, Yki-Jarvinen H, Kantola I, Jula A, et al. Myocardial oxygen consumption is unchanged but efficiency is reduced in patients with essential hypertension and left ventricular hypertrophy. Circulation. 1999;100:2425–30.
- 45. Beanlands RS, Bach DS, Raylman R, Armstrong WF, Wilson V, Montieth M, et al. Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-11 acetate kinetics in patients with dilated cardiomyopathy. J Am Coll Cardiol. 1993;22:1389–98.